Abstract Topics
You can present research in the following categories at the Annual Meeting

Topics

When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract:

A1 – RNA Virus Vectors 
A2 – AAV Vectors – Virology, Vectorology, and Engineering 
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies (excluding Non-Human Primates) 
A4 – AAV Vectors – Clinical/Non-Human Primate Studies  
A5 – AAV Vectors – Product Development Manufacturing 

B1 – Gene Targeting and Gene Correction – In Vivo Studies (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.) 
B2 – Gene Targeting and Gene Correction – In Vitro Studies (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.) 
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids) 
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes) 
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases 
E2 – Cardiovascular and Pulmonary Diseases  

E3 – Neurologic Diseases (excluding Ophthalmic and Auditory Diseases) 
E4 – Ophthalmic and Auditory Diseases 
E5 – Musculo-skeletal Diseases 
E6 – Cancer – Immunotherapy, Cancer Vaccines 
E7 – Cancer – Oncolytic Viruses 

E8 – Cancer – Targeted Gene and Cell Therapy 
E9 – Hematologic and Immunologic Diseases  

F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines) 
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing) 
H1 – Vector Product Engineering, Development or Manufacturing (excluding AAV) 
H2 – Cell Therapy Product Engineering, Development and Manufacturing 
H3 – Pharmacology/Toxicology Studies or Analytics/Assay Development  

I – Gene & Cell Therapy Trials in Progress 

Submit Your Abstract

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.